LIVE WEBINAR: Tuesday, December 8, 2020, 5:00 PM – 6:00 PM Eastern Time

Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Colorectal and Gastroesophageal Cancers

Join us on Tuesday, December 8th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET


Peter C Enzinger, MD
Director, Center for Esophageal and Gastric Cancer
Dana-Farber/Brigham and Women’s Cancer Center
Institute Physician, Dana-Farber Cancer Institute
Associate Professor, Harvard Medical School
Boston, Massachusetts

Zev Wainberg, MD, MSc
Co-Director, GI Oncology Program
Director of Early Phase Clinical Research
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Sumitomo Dainippon Pharma Oncology Inc and Taiho Oncology Inc.

Tuesday, December 8, 2020
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Colorectal Cancer (CRC)

  • Correlation between the right or left location of the primary tumor and outcomes with specific systemic therapies for patients with metastatic CRC (mCRC)
  • Published research findings with encorafenib/cetuximab with or without binimetinib for patients with mCRC with BRAF V600E mutations; FDA approval of encorafenib/cetuximab and appropriate integration into practice
  • Available results from and clinical implications of the Phase II DESTINY-CRC01 study of trastuzumab deruxtecan for patients with HER2-expressing mCRC
  • Clinical, biologic and practical factors in sequencing regorafenib and TAS-102 for patients with multiple regimen-relapsed mCRC
  • Available data with and potential role of TAS-102 in combination with other systemic agents for mCRC and in earlier disease stages
  • Key efficacy and safety results from the Phase III KEYNOTE-177 study of front-line pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) mCRC; implications for clinical practice
  • Rational incorporation of nivolumab, pembrolizumab and nivolumab/ipilimumab into the treatment of MSI-H/dMMR mCRC
  • Early responses observed with anti-PD-1/PD-L1 antibodies in patients with microsatellite-stable mCRC; ongoing investigation of immune checkpoint inhibitors in combination with other systemic approaches (eg, chemotherapy, targeted therapy, other immunotherapy) in this setting
  • Mechanism of action of, early efficacy findings with and ongoing Phase III evaluation of napabucasin for patients with mCRC

MODULE 2: Gastroesophageal Cancers

  • Available findings from recently presented studies attempting to improve on standard perioperative therapy for patients with localized HER2-negative or HER2-positive gastroesophageal adenocarcinoma
  • Clinical and biologic factors affecting the management of newly diagnosed metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancers
  • Integration of ramucirumab into current clinical algorithms for metastatic gastric or GEJ cancer; ongoing investigation of ramucirumab-containing combination regimens
  • Key data sets defining the current role of immune checkpoint inhibition for patients with metastatic gastric, GEJ and esophageal cancers
  • Available data with and patient selection for TAS-102 for previously treated metastatic gastric cancer
  • Efficacy and safety findings from the randomized Phase II DESTINY-Gastric01 study of trastuzumab deruxtecan for HER2-positive advanced gastric or GEJ adenocarcinoma; FDA breakthrough therapy designation and potential clinical role for this agent
  • Other promising agents and strategies under investigation for advanced HER2-negative and HER2-positive gastroesophageal cancers 

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal and gastroesophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop long-term care plans for individuals diagnosed with metastatic colorectal cancer (CRC), considering biomarker profile (BRAF, MSI, HER2), tumor location, prior systemic therapy, symptomatology, performance status and personal goals of treatment.
  • Appreciate published research data with and the FDA approval of encorafenib in combination with cetuximab for patients with relapsed/refractory CRC and a BRAF V600E mutation in order to optimally incorporate this strategy into current clinical algorithms.
  • Evaluate available data with anti-PD-1 and anti-CTLA-4 antibodies for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic CRC, and appropriately integrate these agents into personalized patient care plans.
  • Describe ongoing research to validate the potential benefit of immune checkpoint inhibitors in combination with chemotherapy, targeted therapy or other immunotherapies for patients with MSI-H/dMMR or microsatellite-stable metastatic CRC, and use this information to guide trial design and patient referral.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to individualize the selection and sequence of systemic therapy for locally advanced or metastatic gastric or gastroesophageal cancer.
  • Describe the published research data with and ongoing evaluation of immune checkpoint inhibitors in the management of gastric, gastroesophageal junction and esophageal cancers, and identify patients who may be eligible for this strategy as part of a clinical research study or outside of a protocol setting.
  • Recall the biologic rationale for and available data with the use of trastuzumab deruxtecan for previously treated HER2-positive CRC or gastric/gastroesophageal cancer, and discern the current and potential clinical applicability of this strategy.
  • Devise a rational approach to the incorporation of TAS-102 into treatment algorithms for previously treated locally advanced or metastatic CRC or gastric/gastroesophageal cancer.
  • Identify ongoing clinical trials evaluating novel agents and strategies for CRC and gastroesophageal cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr EnzingerAdvisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Taiho Oncology Inc, Takeda Oncology, Zymeworks. Dr WainbergConsulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Sumitomo Dainippon Pharma Oncology Inc and Taiho Oncology Inc.